Signal transducer and activator of transcription 5A and 5B (STAT5A/STAT5B)

Signal transducer and activator of transcription 5A (STAT5A) and 5B (STAT5B) are highly homologous transcription factors that function as critical mediators in the Janus kinase (JAK)-STAT signaling pathway [8, 15]. They are activated by a diverse array of cytokines and growth factors, including interleukins (IL-2, IL-7), erythropoietin, growth hormone, and prolactin [7, 12]. Upon phosphorylation by JAK kinases, STAT5 proteins form homo- or heterodimers and translocate to the nucleus, where they bind to specific DNA sequences to regulate genes involved in cell survival, proliferation, and differentiation [3, 6]. In many malignancies, particularly hematologic cancers like chronic myeloid leukemia (CML) and various lymphomas, STAT5 is constitutively active, promoting oncogenesis and drug resistance [12, 19]. Constitutive activation often results from upstream mutations in kinases like BCR-ABL or JAK2, or from gain-of-function mutations within the STAT5 genes themselves, such as the STAT5B N642H mutation [15]. Therapeutic strategies include the use of JAK inhibitors to indirectly block STAT5 activation or the development of direct STAT5 inhibitors that target the SH2 domain to prevent dimerization [3, 15]. While STAT5A and STAT5B share over 90% sequence identity, they exhibit non-redundant roles; for instance, STAT5A is vital for mammary gland development, whereas STAT5B is the primary mediator of growth hormone effects on somatic growth [2, 14]. Beyond cancer, STAT5 is essential for normal immune function and postnatal growth, and mutations in these proteins are associated with immunodeficiency and growth disorders [13, 20]. Clinical development of direct inhibitors has faced challenges due to the high structural similarity between STAT family members, but selective targeting of the SH2 domain remains a promising approach to minimize off-target effects [15].

Other names

STAT5STAT5ASTAT5BMGFMammary gland factorSignal transducer and activator of transcription 5

Drugs targeting this molecule primarily act by inhibiting upstream Janus kinases (JAKs) to prevent STAT5 phosphorylation, or by directly binding to the STAT5 SH2 domain to block dimerization and DNA binding [3, 15].